Central nitric oxide blocks vasopressin, oxytocin and atrial natriuretic peptide release and antidiuretic and natriuretic responses induced by central angiotensin II in conscious rats. 2007

Wagner Luis Reis, and Alexandre Giusti-Paiva, and Renato Rizo Ventura, and Lisandra Oliveira Margatho, and Dayane Aparecida Gomes, and Lucila Leico Kagohara Elias, and José Antunes-Rodrigues
Laboratory of Neuroendocrinology, Department of Physiology, School of Medicine of Ribeirao Preto, University of Sao Paulo, Brazil.

The presence of nitric oxide synthase (NOS), the enzyme that catalyses the formation of nitric oxide (NO), in the circumventricular organs and magnocellular neurones suggests an important role of NO in the modulation of vasopressin (AVP) and oxytocin (OT) release. Intracerebroventricular (I.C.V.) injection of angiotensin II (Ang II) stimulates the release of AVP, OT and atrial natriuretic peptide (ANP), with the resultant antidiuretic and natriuretic effects. This study investigated the interaction between nitrergic and angiotensinergic pathways on the release of AVP, OT and ANP and on urinary volume and sodium excretion in water-loaded rats. Unanaesthetized, freely moving, male Wistar rats received two water loads followed by an injection into the lateral ventricle of an inhibitor of NOS (L-NAME), a NO donor [3-morpholinylsydnoneimine chloride (SIN-1) or S-nitroso-N-acetyl penicillamine (SNAP)] or vehicle (isotonic saline) and, 20 min after, they received a second I.C.V. injection of Ang II or vehicle. Injections of L-NAME or Ang II produced an increase in plasma levels of AVP, OT and ANP, a reduction in urinary volume and an increase in sodium excretion. Pretreatment with L-NAME enhanced the Ang II-induced increase in AVP, OT and ANP release, as well as the antidiuresis and natriuresis. Injection of SIN-1 or SNAP did not modify hormonal plasma levels and urinary parameters. In contrast SNAP blocked the AVP, OT and ANP release, as well as antidiuretic and natriuretic responses induced by ANG-II. Thus, the central nitrergic system can act to inhibit AVP, OT and ANP secretion and the antidiuretic and natriuretic effects in response to Ang II.

UI MeSH Term Description Entries
D007276 Injections, Intraventricular Injections into the cerebral ventricles. Intraventricular Injections,Injection, Intraventricular,Intraventricular Injection
D008297 Male Males
D008981 Molsidomine A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS. Morsydomine,Corpea,Corvaton,Duracoron,Fali-Cor,Korvatone,MTW-Molsidomin,Molsi 1A Pharma,Molsi-AZU,Molsi-Puren,Molsibeta,Molsicor,Molsidain,Molsidomin,Molsidomin Heumann,Molsidomin Stada,Molsidomin Von Ct,Molsidomin-Ratiopharm,Molsihexal,Molsiket,SIN-10,Sydnopharm,Fali Cor,Heumann, Molsidomin,MTW Molsidomin,Molsi AZU,Molsi Puren,Molsidomin Ratiopharm,SIN 10,SIN10,Von Ct, Molsidomin
D009318 Natriuresis Sodium excretion by URINATION. Natriureses
D009320 Atrial Natriuretic Factor A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS. ANF,ANP,Atrial Natriuretic Peptide,Atrial Natriuretic Peptides,Atriopeptins,Auriculin,Natriuretic Peptides, Atrial,ANF (1-126),ANF (1-28),ANF (99-126),ANF Precursors,ANP (1-126),ANP (1-28),ANP Prohormone (99-126),ANP-(99-126),Atrial Natriuretic Factor (1-126),Atrial Natriuretic Factor (1-28),Atrial Natriuretic Factor (99-126),Atrial Natriuretic Factor Precursors,Atrial Natriuretic Factor Prohormone,Atrial Natriuretic Peptide (1-126),Atrial Pronatriodilatin,Atriopeptigen,Atriopeptin (1-28),Atriopeptin (99-126),Atriopeptin 126,Atriopeptin Prohormone (1-126),Cardiodilatin (99-126),Cardiodilatin Precursor,Cardionatrin I,Cardionatrin IV,Prepro-ANP,Prepro-CDD-ANF,Prepro-Cardiodilatin-Atrial Natriuretic Factor,Pro-ANF,ProANF,Proatrial Natriuretic Factor,Pronatriodilatin,alpha ANP,alpha-ANP Dimer,alpha-Atrial Natriuretic Peptide,beta-ANP,beta-Atrial Natriuretic Peptide,gamma ANP (99-126),gamma-Atrial Natriuretic Peptide,Natriuretic Peptide, Atrial,Peptide, Atrial Natriuretic,Peptides, Atrial Natriuretic,Prepro ANP,Prepro CDD ANF,Prepro Cardiodilatin Atrial Natriuretic Factor,Pro ANF,alpha ANP Dimer,alpha Atrial Natriuretic Peptide,beta ANP,beta Atrial Natriuretic Peptide,gamma Atrial Natriuretic Peptide
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D009994 Osmolar Concentration The concentration of osmotically active particles in solution expressed in terms of osmoles of solute per liter of solution. Osmolality is expressed in terms of osmoles of solute per kilogram of solvent. Ionic Strength,Osmolality,Osmolarity,Concentration, Osmolar,Concentrations, Osmolar,Ionic Strengths,Osmolalities,Osmolar Concentrations,Osmolarities,Strength, Ionic,Strengths, Ionic
D010121 Oxytocin A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION. Ocytocin,Pitocin,Syntocinon
D003243 Consciousness Sense of awareness of self and of the environment. Consciousnesses
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme

Related Publications

Wagner Luis Reis, and Alexandre Giusti-Paiva, and Renato Rizo Ventura, and Lisandra Oliveira Margatho, and Dayane Aparecida Gomes, and Lucila Leico Kagohara Elias, and José Antunes-Rodrigues
January 1987, Clinical and experimental hypertension. Part A, Theory and practice,
Wagner Luis Reis, and Alexandre Giusti-Paiva, and Renato Rizo Ventura, and Lisandra Oliveira Margatho, and Dayane Aparecida Gomes, and Lucila Leico Kagohara Elias, and José Antunes-Rodrigues
April 2001, Regulatory peptides,
Wagner Luis Reis, and Alexandre Giusti-Paiva, and Renato Rizo Ventura, and Lisandra Oliveira Margatho, and Dayane Aparecida Gomes, and Lucila Leico Kagohara Elias, and José Antunes-Rodrigues
June 1986, European journal of pharmacology,
Wagner Luis Reis, and Alexandre Giusti-Paiva, and Renato Rizo Ventura, and Lisandra Oliveira Margatho, and Dayane Aparecida Gomes, and Lucila Leico Kagohara Elias, and José Antunes-Rodrigues
April 1989, Proceedings of the National Academy of Sciences of the United States of America,
Wagner Luis Reis, and Alexandre Giusti-Paiva, and Renato Rizo Ventura, and Lisandra Oliveira Margatho, and Dayane Aparecida Gomes, and Lucila Leico Kagohara Elias, and José Antunes-Rodrigues
July 1992, Experimental physiology,
Wagner Luis Reis, and Alexandre Giusti-Paiva, and Renato Rizo Ventura, and Lisandra Oliveira Margatho, and Dayane Aparecida Gomes, and Lucila Leico Kagohara Elias, and José Antunes-Rodrigues
August 1990, The Journal of pharmacology and experimental therapeutics,
Wagner Luis Reis, and Alexandre Giusti-Paiva, and Renato Rizo Ventura, and Lisandra Oliveira Margatho, and Dayane Aparecida Gomes, and Lucila Leico Kagohara Elias, and José Antunes-Rodrigues
January 1986, Peptides,
Wagner Luis Reis, and Alexandre Giusti-Paiva, and Renato Rizo Ventura, and Lisandra Oliveira Margatho, and Dayane Aparecida Gomes, and Lucila Leico Kagohara Elias, and José Antunes-Rodrigues
June 1988, Hypertension (Dallas, Tex. : 1979),
Wagner Luis Reis, and Alexandre Giusti-Paiva, and Renato Rizo Ventura, and Lisandra Oliveira Margatho, and Dayane Aparecida Gomes, and Lucila Leico Kagohara Elias, and José Antunes-Rodrigues
February 2019, Journal of neuroendocrinology,
Wagner Luis Reis, and Alexandre Giusti-Paiva, and Renato Rizo Ventura, and Lisandra Oliveira Margatho, and Dayane Aparecida Gomes, and Lucila Leico Kagohara Elias, and José Antunes-Rodrigues
October 2011, Regulatory peptides,
Copied contents to your clipboard!